EUVIMEDEUVIMED entdecken
Crossref

Route‐Gated Lymphatic Delivery of Antigen‐Only Gliadin Nanoparticles for Celiac Disease‐Oriented Immune Modulation

Jiaqi Zhang, Yuan Gao, Yinan Song, Chuyi Bao, Zhaoying Ren, Shiyu Yuan, Yang Yang, Yongjun Wang iD, Hongzhuo Liu iD

Advanced Healthcare Materials · 10.11.2026

DOI: 10.1002/adhm.71970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 10.11.2026. Verfasst von Jiaqi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shenyang Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Celiac disease (CeD) lacks approved pharmacologic therapy. Targeted delivery of antigens to immune inductive sites may provide a means to modulate pathogenic immune responses, yet practical delivery remains challenging. We show that minimal, adjuvant‐free, self‐assembled gliadin nanoparticles (L@GNP) attenuated antibody boosting after exploratory intravenous (i.v.) pre‐exposure. Both soluble gliadin and L@GNP attenuated subsequent anti‐gliadin antibody boosting under the tested i.v. conditions, with L@GNP providing a particulate antigen format with a controlled surface antigen positive rate. Rather than i.v. dosing, subcutaneous (s.c.) administration of L@GNP preferentially accessed draining lymphoid tissues and exhibited temporally coordinated uptake by multiple antigen‐presenting cell (APC) populations, characterized by early CD11b+ myeloid‐cell capture, transient B220+ cell involvement, and sustained enrichment in CD11c+ APCs at later time points. In a short‐term CeD‐like mouse model, L@GNP preserved villus architecture as indicated by higher V/C and reduced intestinal inflammation by lowering Transglutaminase 2 (TGM2) and key cytokines, rebalanced Th1/Th2, and increased Foxp3 expression, whereas a rapamycin‐loaded counterpart (R/L@GNP) did not confer additional benefit at matched antigen doses. These data highlight route‐gated lymphatic access and antigen‐only simplicity as materials design principles for immunomodulatory nanomedicines.

Schlagwörter

Stichwörter der Autor:innen

celiac diseaseimmune modulationintravenous rechallengelymphatic deliveryself‐assembled gliadin nanoparticlessubcutaneous delivery

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
  • College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
  • Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.

ORCID-Profile: Yongjun Wang, Hongzhuo Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shenyang Municipality

Zitieren

APA

Zhang, J., Gao, Y., Song, Y., Bao, C., Ren, Z., Yuan, S., Yang, Y., Wang, Y., & Liu, H. (2026). Route‐Gated Lymphatic Delivery of Antigen‐Only Gliadin Nanoparticles for Celiac Disease‐Oriented Immune Modulation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71970

Vancouver

Zhang J, Gao Y, Song Y, Bao C, Ren Z, Yuan S, et al. Route‐Gated Lymphatic Delivery of Antigen‐Only Gliadin Nanoparticles for Celiac Disease‐Oriented Immune Modulation. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71970

BibTeX
@article{Zhang2026,
  author = {Zhang, Jiaqi and Gao, Yuan and Song, Yinan and Bao, Chuyi and Ren, Zhaoying and Yuan, Shiyu and Yang, Yang and Wang, Yongjun and Liu, Hongzhuo},
  title = {Route‐Gated Lymphatic Delivery of Antigen‐Only Gliadin Nanoparticles for Celiac Disease‐Oriented Immune Modulation},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.71970}
}
Kostenlos starten →